HSBC Maintains Reduce on Eli Lilly, Raises Price Target to $940
HSBC analyst Rajesh Kumar maintains Eli Lilly (NYSE:LLY) with a Reduce and raises the price target from $850 to $940.
Share
Why It Matters
An expert thinks Eli Lilly's stock is still too expensive, even though he raised his price target. This tells you he sees some good things ahead but still thinks the price is too high right now.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.